Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment.
APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to analysis, the global Active Pharmaceutical Ingredient market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $364,169.4 million by 2027. Adoption of biologics in disease management and increasing regulatory approvals in the past year, increasing scope of HPAPI market, patent expiration of major drugs, increasing trend of outsourcing, and increase in geriatric population are some of the factors driving the market growth. The global API market is mainly segmented by synthesis, by business type, by application, and by geography.
The global API market based on synthesis is further divided into synthetic API, Biotech API, and HPAPI.
By synthesis, the synthetic API held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The major factors driving the synthetic chemical API market are patent expiration of synthetic (small molecule drugs), an increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in the incidence of chronic and age-related diseases, rapid growth in the oncology market, technological advancement like cryogenic and continuous flow manufacturing. Biotech API accounted for the share of xx% in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. Increased investment in R&D by pharmaceutical companies for developing biologic drugs, adoption of biological therapies in disease management, increasing outsourcing, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, increasing number of branded drugs going off-patent creating a scope for biosimilars, requirement of novel biologics therapeutics for rare diseases, increasing demand for antibody conjugates, bi or multispecific monoclonal antibodies, and vaccines to contain novel coronavirus infections are few factors driving the biotech API market.
Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines, and others (stem cell therapy and gene therapy). Monoclonal antibodies accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The development of next-generation antibodies such as antibody-drug conjugates and rising venture capital investments and applications of monoclonal antibodies are the factors booming monoclonal antibodies market growth. The vaccine segment is forecasted to grow at a low teen CAGR from 2020 to 2027 owing to the worldwide demand for novel vaccines to treat the coronavirus diseases which emerged as a global pandemic.
Based on the customer base, the global biotech API is further segmented into biologics and biosimilars.
Biologics accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The Biologics market is driven globally due to the adoption of biological therapies in disease management, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, and increasing the elderly population. Biosimilars is expected to grow at an exponential CAGR from 2020 to 2027 owing to patent expiry of biological drugs, low cost compared to biologics, increase in chronic diseases, growing geriatric population, and demand for quality healthcare.
Based on the customer base, the global synthetic API is further divided into branded API and generic API. The Branded API accounted for the largest share in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The Generic API is expected to grow at a high single digit CAGR from 2020 to 2027, due to the patent expiry of blockbuster drugs, rising healthcare expenses, and shift towards generic medicines led by government initiatives.
By business type, the global API market is divided into captive API and merchant API. The Captive market held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The captive API is further divided into branded captive API and generic captive API. The branded captive API accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027 owing to patent protection of blockbuster drugs. The Merchant API market is further divided into branded merchant API and generic merchant API. The Generic merchant API accounted for the largest share in 2020 and is expected to grow at a low teen CAGR from 2020 to 2027. Increasing outsourcing, advanced manufacturing facilities, lack of in-house manufacturing capability, high capital investment, and cost of API manufacturing are some of the factors driving the Merchant API market.
By therapeutic applications, the global API market is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. In the application segment, infectious disease accounted for the largest share in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs. Currently, there is a trend towards precision medicine which further boosts the global oncology API market growth.
The global API market by therapeutic application is segmented into synthetic API application, biotech API application, and HPAPI application market. In synthetic API application, infectious disease accounted for the largest share in 2020 and oncology is expected to grow at a high single digit CAGR from 2020 to 2027.
The active pharmaceutical Ingredients market by region is segmented as North America, Europe, Asia-Pacific, and the Rest of the world (ROW).
By geography, North America held the largest share in 2020 due to patent expiration of the major drugs, rising demand for biotech APIs, market entry of biosimilars, increasing scope of highly potent drugs, and increase in the prevalence of chronic diseases such as cancer, cardiac disease, diseases associated with central nervous system, and musculoskeletal disorder coupled with high healthcare expenditure. Asia-Pacific is the fastest-growing region with a high single digit CAGR from 2020 to 2027 owing to low labor cost, abundance availability of raw materials, infrastructure facility, rise in generic drug demand, increased production capabilities, the presence of a large number of domestic and international players, and concentration of CMO companies.
Some of the key players of Active Pharmaceutical Ingredient (API) market are:
Lonza Group (Switzerland), Boehringer Ingelheim GmbH (Germany), Teva Pharmaceutical Industries Ltd (Israel), Sanofi S.A. (France), Thermo Fisher Sceintific Inc. (Patheon N.V, U.S), Divis Laboratories (India), Olon S.p.A (Italy), Pfizer Inc. (U.S.), Permira funds (Cambrex Corporation U.K.), Carlyle Group (AMRI, U.S.), and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
North America
- U.S.
- Rest of North America
Europe
- Italy
- Germany
- France
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of APAC
Rest of the World (RoW)
- Brazil
- Rest of Latin America
- Middle East and Others
Table of Contents
1 Executive Summary
2 Introduction
2.1 Key Takeaways
2.2 Scope of the Report
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology
2.6.1 Market Size Estimation
2.6.2 Market Breakdown and Data Triangulation
2.6.3 Secondary Sources
2.6.4 Primary Sources
2.6.5 Key Data Points from Secondary Sources
2.6.6 Key Data Points from Primary Sources
2.6.7 Assumptions
3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers and Opportunities
3.3.1.1 Increasing Incidence and Prevalence of Chronic Diseases
3.3.1.2 Adoption of Biologics in Disease Management and Increasing Regulatory Approvals in the Past Year
3.3.1.3 Increasing Scope of HPAPI Market
3.3.1.4 Patent Expiration of Major Drugs
3.3.1.5 Increasing Trend of Outsourcing
3.3.1.6 Increase in the Geriatric Population
3.3.2 Restraints and Threats
3.3.2.1 Contamination of API
3.3.2.2 High Cost for Manufacturing Apis
3.3.2.3 a Requirement of Highly Skilled Technicians
3.3.2.4 Fierce Competition Between API Players
3.3.2.5 Stringent Regulatory Policies and Environmental Concerns
3.4 Regulatory Affairs
3.4.1 International Organization for Standardization
3.4.1.1 Iso 9001: 2015 Quality Management System
3.4.1.2 Iso 13408 Aseptic Processing
3.4.1.3 Iso 14644-1 Clean Room Standards
3.4.2 U.S.
3.4.3 Canada
3.4.4 Mexico
3.4.5 Europe
3.4.6 China
3.4.7 India
3.4.8 Japan
3.4.9 Australia
3.4.10 South Korea
3.4.11 Latin America
3.4.12 Middle East
3.5 Technological Advancements
3.5.1 Introduction
3.5.2 Automation and Control
3.5.3 Continuous Manufacturing
3.5.4 Cryogenic Technology
3.5.5 Single - Use System (Sus)
3.5.6 Mammalian Cell Based Production
3.5.7 Cell Free Based Approach for the Production of Proteins
3.5.8 Advancements in Hpapi Manufacturing
3.6 Porter’S Five Force Analysis
3.6.1 Threat of New Entrants
3.6.2 Threat of Substitutes
3.6.3 Bargaining Power of Suppliers
3.6.4 Bargaining Power of Buyers
3.6.5 Competitive Rivalry
3.7 Supply Chain Analysis
3.8 Market Share Analysis
3.9 Fda Approved API Manufacturing Units
3.10 Pharmaceutical API Production Volume
3.11 Patent Expiry and Anda Approvals
3.12 Drug Master Filing (Dmf)
3.13 Notice of Inspectional Observations (Form 483)
3.14 Repurposed Drugs for Covid-19 Treatment
3.15 Acquisition, Merger, and Expansions
3.16 Collaboration and Agreement Between API Manufacturers
3.17 Selected Top Selling API
3.18 API Manufacturers Revenue and Capabilities Table
4 API Global Market, by Synthesis
4.1 Introduction
4.2 Synthetic API
4.2.1 Synthetic API by Customer Base
4.2.1.1 Branded Synthetic API
4.2.1.2 Generic Synthetic API
4.3 Biotech API
4.3.1 Introduction
4.3.1.1 Monoclonal Antibodies
4.3.1.2 Recombinant Proteins
4.3.1.3 Vaccines
4.3.1.4 Other Biotech API (Cell and Gene Therapy)
4.3.2 Biotech API by Customer Base
4.3.2.1 Biologic API
4.3.2.2 Biosimilar API
4.4 HPAPI
4.4.1 HPAPI by Customer Base
4.4.1.1 Branded HPAPI
4.4.1.2 Generic HPAPI
5 API Global Market, by Business Type
5.1 Introduction
5.2 Captive API by Type
5.2.1 Branded Captive API
5.2.2 Generic Captive API
5.3 Merchant API by Type
5.3.1 Branded Merchant API
5.3.2 Generic Merchant API
6 API Global Market, by Application
6.1 Introduction
6.2 Infectious Diseases
6.3 Oncology
6.4 Cardiovascular Diseases
6.5 Central Nervous System
6.6 Pulmonary Disorders
6.7 Gastrointestinal Disorders
6.8 Endocrine Disorders
6.9 Metabolic Disorders
6.10 Genitourinary Disorders
6.11 Musculoskeletal Disorders
6.12 Other Applications (Anaesthasia, Autoimmune Diseases, Opthalmology, Dental, Pain Management, Gynaecology, Dermatology and Ent)
7 Regional Analysis
7.1 Introduction
7.2 North America
7.2.1 U.S.
7.2.2 Rest of North America
7.3 Europe
7.3.1 Italy
7.3.2 Germany
7.3.3 France
7.3.4 Rest of Europe
7.4 APAC
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest of APAC
7.5 RoW
7.5.1 Brazil
7.5.2 Rest of Latam
7.5.3 Middle East & Others
8 Competitive Landscape
8.1 Introduction
8.2 Product Approvals
8.3 Agreements
8.4 Expansions
8.5 Collaborations
8.6 Product Launch
8.7 Partnership
8.8 Acquisitions
8.9 Others
9 Major Companies
9.1 Carlyle Group (Albany Molecular Research Inc)
9.1.1 Overview
9.1.2 Financials
9.1.3 Product Portfolio
9.1.4 Key Developments
9.1.5 Business Strategy
9.1.6 SWOT Analysis
9.2 Boehringer Ingelheim International GmbH
9.2.1 Overview
9.2.2 Financials
9.2.3 Product Portfolio
9.2.4 Key Developments
9.2.5 Business Strategy
9.2.6 SWOT Analysis
9.3 Divis Laboratories
9.3.1 Overview
9.3.2 Financials
9.3.3 Product Portfolio
9.3.4 Key Developments
9.3.5 Business Strategy
9.3.6 SWOT Analysis
9.4 Lonza Group Ltd.
9.4.1 Overview
9.4.2 Financials
9.4.3 Product Portfolio
9.4.4 Key Developments
9.4.5 Business Strategy
9.4.6 SWOT Analysis
9.5 Olon S.P.A.
9.5.1 Overview
9.5.2 Financials
9.5.3 Product Portfolio
9.5.4 Key Developments
9.5.5 Business Strategy
9.5.6 SWOT Analysis
9.6 Permira Funds (Cambrex Corporation U.K.)
9.6.1 Overview
9.6.2 Financials
9.6.3 Product Portfolio
9.6.4 Key Developments
9.6.5 Business Strategy
9.6.6 SWOT Analysis
9.7 Pfizer Inc.
9.7.1 Overview
9.7.2 Financials
9.7.3 Product Portfolio
9.7.4 Key Developments
9.7.5 Business Strategy
9.7.6 SWOT Analysis
9.8 Sanofi
9.8.1 Overview
9.8.2 Financials
9.8.3 Product Portfolio
9.8.4 Key Developments
9.8.5 Business Strategy
9.8.6 SWOT Analysis
9.9 Teva Pharmaceutical Industries Limited.
9.9.1 Overview
9.9.2 Financials
9.9.3 Product Portfolio
9.9.4 Key Developments
9.9.5 Business Strategy
9.9.6 SWOT Analysis
9.10 Thermo Fisher Scientific Inc
9.10.1 Overview
9.10.2 Financials
9.10.3 Product Portfolio
9.10.4 Key Developments
9.10.5 Business Strategy
9.10.6 SWOT Analysis
List of Tables
Table 1 API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 2 Global Small Molecule API Revenue ($Mn), Average Selling Price ($/Kg) and Production in Tons, by Application (2020)
Table 3 Global Small Molecule Volume and Utilization, Cmo Volume and Utilization, (2019-2027) (Million Litres)
Table 4 Global Small Molecule API Production, by Application, (2019-2027) (Tons)
Table 5 Global Biologics Volume and Utilization, Cmo Volume and Utilization, (2019-2027) (Million Litres)
Table 6 Global Small Molecule API Production, (2019-2027) (Metric Tons)
Table 7 Global Biologics API Production, (2019-2027) (Metric Tons)
Table 8 Global API Production, (2019-2027) (Metric Tons)
Table 9 Patent Expiry of Synthetic API Drugs, (2017 – 2022)
Table 10 Patent Expiry of Biotech API Drugs, (2018 – 2028)
Table 11 Anda Approvals: Small Molecules - Generics, (2020 – 2021)
Table 12 Anda Approvals: Biosimilars, (2020)
Table 13 Companies Acquisition and Merger, (2018 – 2020)
Table 14 Expansions, (2019 – 2021)
Table 15 Collaborations and Agreements, (2019 – 2021)
Table 16 API Global Market Revenue, by Synthesis, (2019-2027) ($Mn)
Table 17 Synthetic API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 18 Synthetic API Global Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 19 Branded Synthetic API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 20 Generic Synthetic API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 21 Biotech API Global Market Revenue, by Product Type, (2019-2027) ($Mn)
Table 22 Biotech API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 23 Monoclonal Antibodies Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 24 Recombinant Proteins Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 25 Vaccines Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 26 Other Biotech API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 27 Biotech API Global Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 28 Biologic API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 29 Biosimilar API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 30 Hpapi Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 31 Hpapi Global Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 32 Branded Hpapi Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 33 Generic Hpapi Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 34 API Global Market Revenue, by Business Type, (2019-2027) ($Mn)
Table 35 Captive API Global Market Revenue, by Type, (2019-2027) ($Mn)
Table 36 Captive API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 37 Branded Captive API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 38 Generic Captive API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 39 Merchant API Global Market Revenue, by Type, (2019-2027) ($Mn)
Table 40 Merchant API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 41 Branded Merchant API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 42 Generic Merchant API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 43 API Global Market Revenue, by Application, (2019-2027) ($Mn)
Table 44 Synthetic API Global Market Revenue, by Application, (2019-2027) ($Mn)
Table 45 Biotech API Global Market Revenue, by Application, (2019-2027) ($Mn)
Table 46 Hpapi Global Market Revenue, by Application, (2019-2027) ($Mn)
Table 47 Infectious Diseases API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 48 Synthetic Infectious Diseases API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 49 Biotech Infectious Diseases API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 50 Hpapi Infectious Diseases Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 51 Oncology API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 52 Synthetic Oncology API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 53 Biotech Oncology API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 54 Hpapi Oncology Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 55 Cardiovascular Diseases API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 56 Synthetic Cardiovascular Diseases API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 57 Biotech Cardiovascular Diseases API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 58 Hpapi Cardiovascular Diseases Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 59 Central Nervous System API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 60 Synthetic Central Nervous System API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 61 Biotech Central Nervous System API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 62 Hpapi Central Nervous System Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 63 Pulmonary Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 64 Synthetic Pulmonary Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 65 Biotech Pulmonary Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 66 Hpapi Pulmonary Disorders Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 67 Gastrointestinal Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 68 Synthetic Gastrointestinal Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 69 Biotech Gastrointestinal Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 70 Gastrointestinal Disorders Hpapi Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 71 Endocrine Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 72 Synthetic Endocrine Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 73 Biotech Endocrine Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 74 Hpapi Endocrine Disorders Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 75 Metabolic Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 76 Synthetic Metabolic Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 77 Biotech Metabolic Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 78 Hpapi Metabolic Disorders Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 79 Genitourinary Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 80 Synthetic Genitourinary Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 81 Biotech Genitourinary Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 82 Hpapi Genitourinary Disorders Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 83 Musculoskeletal Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 84 Synthetic Musculoskeletal Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 85 Biotech Musculoskeletal Disorders API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 86 Hpapi Musculoskeletal Disorders Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 87 Other Applications API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 88 Synthetic Other Applications API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 89 Biotech Other Applications API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 90 Hpapi Other Applications Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 91 API Global Market Revenue, by Region, (2019-2027) ($Mn)
Table 92 North America API Market Revenue, by Synthesis, (2019-2027) ($Mn)
Table 93 North America Biotech API Market Revenue, by Product Type, (2019-2027) ($Mn)
Table 94 North America Synthetic API Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 95 North America Biotech API Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 96 North America Hpapi Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 97 North America API Market Revenue, by Business Type, (2019-2027) ($Mn)
Table 98 North America Captive API Market Revenue, by Type, (2019-2027) ($Mn)
Table 99 North America Merchant API Market Revenue, by Type, (2019-2027) ($Mn)
Table 100 North America API Market Revenue, by Application, (2019-2027) ($Mn)
Table 101 North America Synthetic API Market Revenue, by Application, (2019-2027) ($Mn)
Table 102 North America Biotech API Market Revenue, by Application, (2019-2027) ($Mn)
Table 103 North America Hpapi Market Revenue, by Application, (2019-2027) ($Mn)
Table 104 North America API Market Revenue, by Country, (2019-2027) ($Mn)
Table 105 Europe API Market Revenue, by Synthesis, (2019-2027) ($Mn)
Table 106 Europe Biotech API Market Revenue, by Product Type, (2019-2027) ($Mn)
Table 107 Europe Synthetic API Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 108 Europe Biotech API Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 109 Europe Hpapi Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 110 Europe API Market Revenue, by Business Type, (2019-2027) ($Mn)
Table 111 Europe Captive API Market Revenue, by Type, (2019-2027) ($Mn)
Table 112 Europe Merchant API Market Revenue, by Type, (2019-2027) ($Mn)
Table 113 Europe API Market Revenue, by Application, (2019-2027) ($Mn)
Table 114 Europe Synthetic API Market Revenue, by Application, (2019-2027) ($Mn)
Table 115 Europe Biotech API Market Revenue, by Application, (2019-2027) ($Mn)
Table 116 Europe Hpapi Market Revenue, by Application, (2019-2027) ($Mn)
Table 117 Europe API Market Revenue, by Country, (2019-2027) ($Mn)
Table 118 APAC API Market Revenue, by Synthesis, (2019-2027) ($Mn)
Table 119 APAC Biotech API Market Revenue, by Product Type, (2019-2027) ($Mn)
Table 120 APAC Synthetic API Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 121 APAC Biotech API Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 122 APAC Hpapi Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 123 APAC API Market Revenue, by Business Type, (2019-2027) ($Mn)
Table 124 APAC Captive API Market Revenue, by Type, (2019-2027) ($Mn)
Table 125 APAC Merchant API Market Revenue, by Type, (2019-2027) ($Mn)
Table 126 APAC API Market Revenue, by Application, (2019-2027) ($Mn)
Table 127 APAC Synthetic API Market Revenue, by Application, (2019-2027) ($Mn)
Table 128 APAC Biotech API Market Revenue, by Application, (2019-2027) ($Mn)
Table 129 APAC Hpapi Market Revenue, by Application, (2019-2027) ($Mn)
Table 130 APAC API Market Revenue, by Country, (2019-2027) ($Mn)
Table 131 Row API Market Revenue, by Synthesis, (2019-2027) ($Mn)
Table 132 Row Biotech API Market Revenue, by Product Type, (2019-2027) ($Mn)
Table 133 Row Synthetic API Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 134 Row Biotech API Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 135 Row Hpapi Market Revenue, by Customer Base, (2019-2027) ($Mn)
Table 136 Row API Market Revenue, by Business Type, (2019-2027) ($Mn)
Table 137 Row Captive API Market Revenue, by Type, (2019-2027) ($Mn)
Table 138 Row Merchant API Market Revenue, by Type, (2019-2027) ($Mn)
Table 139 Row API Market Revenue, by Application, (2019-2027) ($Mn)
Table 140 Row Synthetic API Market Revenue, by Application, (2019-2027) ($Mn)
Table 141 Row Biotech API Market Revenue, by Application, (2019-2027) ($Mn)
Table 142 Row Hpapi Market Revenue, by Application, (2019-2027) ($Mn)
Table 143 Row API Market Revenue, by Country, (2019-2027) ($Mn)
Table 144 Product Approvals
Table 145 Agreements
Table 146 Expansions
Table 147 Collaborations
Table 148 Product Launch
Table 149 Partnership
Table 150 Acquisitions
Table 151 Others
Table 152 Boehringer Ingelheim: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 153 Boehringer Ingelheim: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 154 Boehringer Ingelheim: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 155 Divis Laboratories Ltd: Total Revenue and R&D Expenses (2018-2020) ($Mn)
Table 156 Divis Laboratories Ltd: Total Revenue, by Geography (2018-2020) ($Mn)
Table 157 Lonza Group: Total Revenue & R&D Expenses (2018 -2020) ($Mn)
Table 158 Lonza Group: Total Revenue, by Segment, (2018-2020) ($Mn)
Table 159 Lonza Group: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 160 Pfizer Inc: Total Revenue and R&D Expenses, (2018-2019) ($Mn)
Table 161 Pfizer Inc: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 162 Pfizer Inc: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 163 Sanofi: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 164 Sanofi: Total Revenue by Segment (2018-2020) ($Mn)
Table 165 Sanofi: Total Revenue by Region (2018-2020) ($Mn)
Table 166 Teva Pharmaceutical Industries Limited: Total Revenue and R&D Expenses (2018-2020) ($Mn)
Table 167 Teva Pharmaceutical Industries Limited: Total Revenue by Segment (2018-2020) ($Mn)
Table 168 Teva Pharmaceutical Industries Limited: Total Revenue by Geography (2018-2020) ($Mn)
Table 169 Thermo Fisher Scientific Inc: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 170 Thermo Fisher Scientific Inc: Total Revenue, by Segment, (2018-2020) ($Mn)
Table 171 Thermo Fisher Scientific Inc: Total Revenue, by Geography, (2018-2020) ($Mn)
List of Figures
Figure 1 API Global Market Revenue, by Region (2019-2027) ($Mn)
Figure 2 Research Methodology: API Global Market
Figure 3 API Global Market: Top-Down and Bottom-Up Approach
Figure 4 API Global Market: Forecasting Model
Figure 5 API Global Market: Market Breakdown and Data Triangulation
Figure 6 API Global Market Segmentation
Figure 7 Market Dynamics
Figure 8 API Global Market: Porter’S Analysis
Figure 9 API Global Market: Supply Chain Analysis
Figure 10 Global API Market Share Analysis, 2020 (%)
Figure 11 Fda Approved Global API Manufacturing Landscape
Figure 12 Small Molecule API Production by Application (2020), In-House V/S Cmo (2019 – 2027) (Tons) and Global Manufacturing Capacities (2020) (Litres)
Figure 13 Global Total API and Cmo Production (2019 – 2027) (Metric Tons)
Figure 14 Patent Expiry of Small Molecules (2017-2022)
Figure 15 Patent Expiry (2017-2022) and Anda Approvals (2020 -2021), by Application Share (%)
Figure 16 API Dmf Filed by Countries (2020) (No’S)
Figure 17 API Dmf Filed, by Company (2020) (No’S)
Figure 18 Form 483 Non-Compliance, by Country (2020) (No’S)
Figure 19 API Global Market Share, by Synthesis, by Customer Base and Biotech API by Product Type (2020) (%)
Figure 20 Biotech API Global Market Share, by Product Type (2020) (%)
Figure 21 Vaccines Global Market Share, by Region, (2020 V/S 2027) (%)
Figure 22 Generic Hpapi Global Market Share, by Region, (2020 V/S 2027) (%)
Figure 23 API Global Market Share, by Business Type, Captive API and Merchant API by Type (2020) (%)
Figure 24 Captive API Global Market Share, by Region, (2020 V/S 2027) (%)
Figure 25 API Global Market Share, by Application (2020) (%), CAGR (%)
Figure 26 Synthetic API Global Market Share, by Application (2020) (%), CAGR (%)
Figure 27 Biotech API Global Market Share, by Application, (2020) (%), CAGR (%)
Figure 28 Hpapi Global Market Share, by Application, (2020) %, CAGR (%)
Figure 29 Biotech Infectious Disease API Global Market Share, by Region, (2020 V/S 2027) (%)
Figure 30 Metabolic Disorder API Global Market Share, by Region, (2020 V/S 2027) (%)
Figure 31 API Global Market Revenue, by Region (2019-2027) ($Mn), CAGR (%)
Figure 32 API Global Market Share, by Region and by Country (2020) (%)
Figure 33 North America API Market Share, by Synthesis and Biotech API Market, by Product Type (2020) (%)
Figure 34 North America Synthetic Api, Biotech API and Hpapi Market Share, by Customer Base (2020 V/S 2027) (%)
Figure 35 North America API Market Share, by Business Type, Captive API and Merchant API Market, by Type (2020 V/S 2027) (%)
Figure 36 North America API Market Share, by Application (2020 V/S 2027) (%)
Figure 37 North America Synthetic API Market Share, by Application (2020 V/S 2027) (%)
Figure 38 North America Biotech API Market Share, by Application (2020 V/S 2027) (%)
Figure 39 North America Hpapi Market Share, by Application (2020 V/S 2027) (%)
Figure 40 North America API Market Share, by Country (2020 V/S 2027) (%)
Figure 41 U.S. API Market Revenue, by Synthesis Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 42 U.S. API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 43 U.S. Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 44 U.S. Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 45 U.S. Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 46 Rest of N.A. API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 47 Rest of N.A. API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 48 Rest of N.A. Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 49 Rest of N.A. Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 50 Rest of N.A. Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 51 Europe API Market Share, by Synthesis and Biotech API Market, by Product Type (2020) (%)
Figure 52 Europe Synthetic Api, Biotech API and Hpapi Market Share, by Customer Base (2020 V/S 2027) (%)
Figure 53 Europe API Market Share, by Business Type, Captive API and Merchant API Market, by Type (2020 V/S 2027) (%)
Figure 54 Europe API Market Share, by Application (2020 V/S 2027) (%)
Figure 55 Europe Synthetic API Market Share, by Application (2020 V/S 2027) (%)
Figure 56 Europe Biotech API Market Share, by Application (2020 V/S 2027) (%)
Figure 57 Europe Hpapi Market Share, by Application (2020 V/S 2027) (%)
Figure 58 Europe API Market Share, by Country (2020 V/S 2027) (%)
Figure 59 Italy API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 60 Italy API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 61 Italy Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 62 Italy Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 63 Italy Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 64 Germany API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 65 Germany API Market Revenue, by Application (2020V/S 2027) ($Mn)
Figure 66 Germany Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 67 Germany Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 68 Germany Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 69 France API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 70 France API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 71 France Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 72 France Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 73 France Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 74 Rest of Europe API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 75 Rest of Europe API Market Revenue, by Application (2020 V/S 202) ($Mn)
Figure 76 Rest of Europe Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 77 Rest of Europe Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 78 Rest of Europe Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 79 APAC API Market Share, by Synthesis and Biotech API Market, by Product Type (2020 V/S 2027) (%)
Figure 80 APAC Synthetic Api, Biotech API and Hpapi Market Share, by Customer Base (2020 V/S 2027) (%)
Figure 81 APAC API Market Share, by Business Type, Captive API and Merchant API Market, by Type (2020 V/S 2027) (%)
Figure 82 APAC API Market Share, by Application (2020 V/S 2027) (%)
Figure 83 APAC Synthetic API Market Share, by Application (2020 V/S 2027) (%)
Figure 84 APAC Biotech API Market Share, by Application (2020 V/S 2027) (%)
Figure 85 APAC Hpapi Market Share, by Application (2020 V/S 2027) (%)
Figure 86 Rest of APAC API Market Share, by Country (2020 V/S 2027) (%)
Figure 87 China API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 88 China API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 89 China Synthetic API Market Revenue, by Application, (2020 V/S 2027) ($Mn)
Figure 90 China Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 91 China Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 92 Japan API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 93 Japan API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 94 Japan Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 95 Japan Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 96 Japan Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 97 India API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 98 India API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 99 India Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 100 India Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 101 India Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 102 Rest of APAC API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 103 Rest of APAC API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 104 Rest of APAC Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 105 Rest of APAC Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 106 Rest of APAC Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 107 Row API Market Share, by Synthesis and Biotech API Market, by Type (2020 V/S 2027) (%)
Figure 108 Row Synthetic Api, Biotech API and Hpapi Market Share, by Customer Base (2020 V/S 2027) (%)
Figure 109 Row API Market Share, by Business Type, Captive API and Merchant API Market, by Type (2020 V/S 2027) (%)
Figure 110 Row API Market Share, by Application (2020 V/S 2027) (%)
Figure 111 Row Synthetic API Market Share, by Application (2020 V/S 2027) (%)
Figure 112 Row Biotech API Market Share, by Application (2020 V/S 2027) (%)
Figure 113 Row Hpapi Market Share, by Application (2020 V/S 2027) (%)
Figure 114 Row API Share, by Country (2020 V/S 2027) (%)
Figure 115 Brazil API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 116 Brazil API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 117 Brazil Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 118 Brazil Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 119 Brazil Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 120 Rest of Latam API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027) ($Mn)
Figure 121 Rest of Latam API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 122 Rest of Latam Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 123 Rest of Latam Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 124 Rest of Latam Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 125 Middle East & Others API Market Revenue, by Business Type, Biotech API Market Revenue, by Product Type and API Market, by Business Type (2020 V/S 2027)($Mn)
Figure 126 Middle East & Others API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 127 Middle East & Others Synthetic API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 128 Middle East & Others Biotech API Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 129 Middle East & Others Hpapi Market Revenue, by Application (2020 V/S 2027) ($Mn)
Figure 130 Key Growth Strategies, (2019-2021)
Figure 131 SWOT: Albany Molecular Research Inc
Figure 132 SWOT: Boehringer Ingelheim GmbH
Figure 133 SWOT: Divis Laboratories
Figure 134 SWOT: Lonza Group
Figure 135 SWOT: Olon S.P.A
Figure 136 SWOT: Cambrex Corporation
Figure 137 SWOT: Pfizer Inc.
Figure 138 SWOT: Sanofi
Figure 139 SWOT: Teva Pharmaceutical Industries Limited
Figure 140 SWOT: Thermo Fisher Scientific
Samples
LOADING...
Companies Mentioned
- Aarti Drugs Ltd.
- AbbVie Inc.
- AbCellera Biologics Inc.
- Abclonal Inc.
- Acadia Pharmaceuticals Inc.
- Aceto
- ACIC Pharmaceuticals Inc.
- Adimmune corporation
- Advance Pharmaceuticals, LLC
- Aileron Therapeutics Inc.
- Ajanta Pharma Limited
- Ajinomoto Bio-Pharma
- Albemarle Corporation
- Alcami Corporation, Inc.
- Alembic Pharmaceuticals Ltd.
- Alkem Laboratories Ltd.
- Alkermes Plc
- Almac group
- Almelo Private Limited
- Alpic Remedies Ltd.
- Alven Laboratories
- Ambio Pharma Inc.
- Amega Biotech S.A.
- Amgen Inc.
- Amneal Pharmaceuticals LLC
- Amoytop Biotech
- Angelini Holding S.p.A.
- Aprogen
- Aputit LLC
- Aravive Inc.
- Arena Pharmaceuticals, Inc.
- Arevipharma GmbH
- Artesan Pharma GmbH & Co. KG
- Aspire Lifesciences Pvt., Ltd.
- Astellas Pharma Inc.
- AstraZeneca plc
- Aurinia Pharmaceuticals Inc.
- Aurobindo Pharma Ltd.
- Avrobio Inc.
- AZAD Pharmaceutical Ingredients AG
- Bachem holding AG
- Bal Pharma Ltd.
- BASF SE
- Baxter International Inc.
- Bayer AG
- Bio Elpida
- Bio Genomics Ltd.
- Bio Marin Pharmaceuticals Inc.
- Biocin Healthcare
- Biocon Ltd.
- Biogen Inc.
- Bionow
- BioNTech SE
- Biophore India pharmaceuticals Pvt Ltd
- Biosint S.p.A.
- Biotechnica Pharma Global
- Biovian
- Blanver Farmoquimica
- Boehringer Ingelheim GmbH
- Brammer bio
- Brawn Biotech Ltd.
- Bright Path laboratories
- Bristol-Meyers Squibb
- Cadila Pharmaceuticals Ltd.
- Carlyle Group (AMRI)
- Catalent Inc.
- Cayman chemical
- Celgene Corporation
- Celltrion Healthcare
- Century Pharmaceuticals Ltd.
- Cerbios - pharma S.A.
- CFM Group (AMSA S.P.A)
- Changzhou Pharmaceutical Factory
- ChemCon GmbH
- China Chemical & Pharmaceutical Co., Ltd.
- Chongqing Huapont Pharmaceutical Co., Ltd.
- Cipla Limited
- CKD Bio
- Coba pharma S.L.U
- Consort Medical Plc.
- Corden Pharma International GmbH
- Cosmo Pharmaceuticals
- CTX Life Sciences Pvt. Ltd.
- Daiichi Sankyo Company, Limited
- Daito Pharmaceutical Co., Ltd.
- Dalton Pharma Services
- DCS Pharma AG
- Delpharm SAS
- Dishman Carbogen Amcis Limited
- Divis laboratories Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- Elusys Therapeutic, Inc.
- Emcure Pharmaceuticals Ltd.
- Enaltec Labs Private Limited.
- Eprius Biopharmaceuticals Inc.
- Ercros S.A
- Estechpharma Co., Ltd.
- Esteve Química
- Everest Organics Limited
- Evonik Industries AG (Evonic healthcare)
- F. Hoffmann-La Roche Ltd
- Fabbrica Italiana Sintetici S.p.A.
- Fareva S.A
- Farmabios SpA
- Farmhispania Group
- Ferrer group (Interquim, S.A.)
- Ferring Pharmaceuticals
- Flamma S.p.A.
- Florentis Pharmaceuticals Pvt., Ltd.
- Formosa Laboratories Inc.
- Fresenius SE & co. Kgaa
- Fujifilm Corporation
- Generex Biotechnology Corperation
- Gentec Pharmaceutical Group S.A
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Glenmark Generics Ltd.
- Gnosis S.p.A.
- Granules India Ltd.
- GVK Industries Limited (GVK Bioscience)
- Haoyuan Chemexpress Co.Ltd.
- Harbour BioMed
- Harman Finochem Limited
- Heni Chemical Industries
- Heraues Holding GmbH
- Hetero Labs Ltd.
- Honour Lab Ltd.
- Hovione
- Huvapharma
- Hybio Pharmaceutical Co., Ltd.
- iBio Inc
- Icrom SpA
- Inabata France S.A.S.
- Inalco S.p.A.
- Indena S.p.A
- Inpellis Inc.
- Intas Pharmaceuticals Ltd.
- Jeil Pharmaceutical Co. Ltd.
- Johnson & Johnson
- Jubilant Life Sciences
- Katsura Chemical Co.,Ltd.
- KBI Biopharma, Inc.
- Kern Pharma, S.L.
- Kleos pharma
- Kongo Yakuhin Co., Ltd.
- Kosher Pharmaceuticals
- KYORIN Holdings, Inc. (KYORIN Pharmaceutical Co., Ltd.)
- Lannett Co. Inc.
- Laurus Labs.
- Lebsa
- LGM Pharma
- Libbs Farmacêutica
- Liptis Pharmaceuticals USA Inc.
- Lonza Group
- Lotus Pharmaceutical Co., Ltd.
- Lupin Limited
- Lusochimica S.p.A
- Macleods pharmaceutical Ltd.
- Magle Chemoswed AB
- Mallinckrodt Pharmaceuticals
- Medichem S.A
- Megafine Pharma Ltd
- Mehta API
- Merck KGaA
- Metrochem API
- Micro Labs Ltd.
- Minakem S.A
- Moehs Iberica S.L.
- Molcan Corporation
- Morepen Laboratories Ltd.
- MSN Laboratories Pvt.Ltd.
- MViyeS Pharma Ventures Private Limited
- Natco Pharma Ltd.
- Neovacs
- Neuland Laboratories Ltd
- Neuraxpharm Arzneimittel GmbH
- Nifty Labs Pvt Ltd.
- Norchim SAS
- Novartis International AG
- Novasep Hodlings SAS
- Novo Nordisk A/S
- Novocap S.A.
- Nuclius Lifesciences
- Ofichem B.V.
- Olainfarm AS
- Olon S.p.A
- Optimus Pharma Private Ltd.
- Optum, Inc.
- Orgenesis Inc.
- Orion Oy (Fermion Oy)
- Outlook Therapeutics, Inc.
- Paratek pharmaceuticals Inc.
- Permira funds (Cambrex Corporation)
- Perrigo Company plc
- Personalized Stem Cells, Inc.
- Pfanstiehl Inc.
- Pfizer Inc.
- Pharmaceutical International Inc.
- PharmaZell Group
- Phyton Biotech LLC
- Pierre Fabre Group
- Piramal Pharma Solutions
- Polpharma B2B
- Prajna Generics Pvt. Ltd.
- Precise Group
- Precision BioSciences, Inc.
- Princeton Biomolecular Research Inc
- ProBiogen AG
- Prozomix Limited
- Raks Pharma Pvt Ltd.
- Recipharm AB
- Regeneron Pharmaceuticals, Inc.
- Reine Lifescience
- Reva Pharma Pvt., Ltd.
- Rinque pharma S.A
- Rochem International Inc.
- RPG Life Sciences Ltd.
- Rxn Chemicals Pvt. Ltd.
- Saamya Biotech (India) Ltd.
- Sajjala Bio Labs
- Samsung Biologics Co. Ltd.
- Saneca Pharmaceuticals a.s.
- Sanofi S.A.
- ScinoPharm Taiwan Ltd.
- Seattle Genetics Inc.
- Seqens Group
- Serenity Pharmaceuticals Corp
- Sermonix Pharmaceuticals
- Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
- Shanghai Henlius Biotech, Inc.
- Shenzhen Haorui Industrial Dev.
- Shilpa Medicare Limited
- Shiono Chemical Co., Ltd.
- Shionogi & Co. Ltd.
- Shreeji Pharma International
- Sichuan Clover Biopharmaceuticals, Inc.
- Siegfried Holdinngs AG
- SM Biomed SDN. BHD
- Smilax Laboratories Limited
- SMS Pharmaceuticals Limited
- Spark therapeutics
- Srini Pharmaceuticals Ltd.
- STADA Arzneimittel AG
- Standard Chemical & Pharmaceutical Co.
- Sterling Biotech Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Suven Life Science Ltd
- Suzhou Ryway Biotech
- Symbiotec Pharma lab Pvt., Ltd
- Synergene Active Ingredients Pvt, Ltd.
- Syn-tech chem. And Pharma.Co., Ltd.
- Takeda Pharmaceutical Company Ltd.
- Taro Pharmaceutical Industries Ltd.
- TB Alliance
- Temad Co.
- Tetraphase Pharmaceutical Inc.
- Teva Pharmaceutical Industries Ltd
- TherapeuticMd Inc.
- Theravance biopharma, Inc.
- Thermo Fisher Scientific
- TiGenix NV
- Tonix Pharmaceuticals
- Torrent Pharmaceuticals, Ltd.
- TPG Biotech
- trenzyme GmbH
- Trimax Bio Sciences (P) Limited
- Umicore N.V.
- Unichem Laboratories Ltd.
- Union Quimico Farmaceutica, S.A.
- Unique Biotech Ltd.
- USV Private Ltd.
- Vaishali Pharma Ltd.
- Vertex Pharmaceuticals
- Viatris Inc. (Mylan N.V./Upjohn Pfizer Inc.)
- Vir Biotechnology, Inc.
- Viruj Pharmaceuticals Pvt, Ltd.
- Vivimed labs Ltd.
- Wanbury Ltd.
- Wavelength Pharmaceuticals
- Welt Care Lifesciences Pvt., Ltd.
- Wockhardt
- WuXi AppTec (STA Pharmaceutical Co., Ltd.)
- WuXi Biologics
- Xellia Pharmaceuticals
- Xiamen Amoytop Biotech Co., Ltd.
- Yabao Pharmaceutical Group Co., Ltd.
- Yung Zip Chemical Industrial Co., Ltd.
- Zambon group (Zach)
- Zcl Chemicals Ltd.
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Zydus Cadila
